Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study

Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Toshiharu Shoji, Nobuyuki Miyasaka, Takao Koike

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives. To evaluate the long-term efficacy and safety of certolizumab pegol (CZP) treatment and to assess the efficacy of two CZP maintenance dosing schedules in Japanese rheumatoid arthritis (RA) patients who could not receive methotrexate (MTX). Methods. HIKARI double-blind (DB) patients were entered into an open-label extension (OLE) study. Patients withdrawn at 16 weeks due to lack of efficacy and DB completers without a 24-week American College of Rheumatology (ACR)20 response received CZP 200 mg every 2 weeks (Q2W). DB completers with 24-week ACR20 responses were randomized to CZP 200 mg Q2W or CZP 400 mg every 4 weeks. Results. The ACR20/ACR50/ACR70 response rates of DB completers (n = 98) were 82.7%/56.1%/34.7% at OLE entry, and 83.7%/65.3%/48.0% at 52 weeks, respectively. Other clinical, functional, and radiographic outcomes were sustained during long-term administration of CZP, even without MTX. No new unexpected adverse events were observed during long-term CZP treatment. The efficacy and safety of CZP treatment were similar between the two dosing schedules. Conclusions. Long-term CZP administration is efficacious and safe for RA patients. No obvious differences in clinical efficacy and safety were observed between the two dosing schedules. The choice between two maintenace regimens adds flexibility in administration schedules for RA patients and physicians.

Original languageEnglish
Pages (from-to)725-733
Number of pages9
JournalModern Rheumatology
Volume24
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Methotrexate
Rheumatoid Arthritis
Safety
Appointments and Schedules
Certolizumab Pegol
Therapeutics
Maintenance
Physicians

Keywords

  • Certolizumab pegol
  • Monotherapy
  • Rheumatoid arthritis
  • TNF inhibitor
  • TNFα

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate : 52-week results from an open-label extension of the HIKARI study. / Tanaka, Yoshiya; Yamamoto, Kazuhiko; Takeuchi, Tsutomu; Yamanaka, Hisashi; Ishiguro, Naoki; Eguchi, Katsumi; Watanabe, Akira; Origasa, Hideki; Shoji, Toshiharu; Miyasaka, Nobuyuki; Koike, Takao.

In: Modern Rheumatology, Vol. 24, No. 5, 2014, p. 725-733.

Research output: Contribution to journalArticle

Tanaka, Yoshiya ; Yamamoto, Kazuhiko ; Takeuchi, Tsutomu ; Yamanaka, Hisashi ; Ishiguro, Naoki ; Eguchi, Katsumi ; Watanabe, Akira ; Origasa, Hideki ; Shoji, Toshiharu ; Miyasaka, Nobuyuki ; Koike, Takao. / Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate : 52-week results from an open-label extension of the HIKARI study. In: Modern Rheumatology. 2014 ; Vol. 24, No. 5. pp. 725-733.
@article{6461008cd09442b8baee108beaab02e9,
title = "Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study",
abstract = "Objectives. To evaluate the long-term efficacy and safety of certolizumab pegol (CZP) treatment and to assess the efficacy of two CZP maintenance dosing schedules in Japanese rheumatoid arthritis (RA) patients who could not receive methotrexate (MTX). Methods. HIKARI double-blind (DB) patients were entered into an open-label extension (OLE) study. Patients withdrawn at 16 weeks due to lack of efficacy and DB completers without a 24-week American College of Rheumatology (ACR)20 response received CZP 200 mg every 2 weeks (Q2W). DB completers with 24-week ACR20 responses were randomized to CZP 200 mg Q2W or CZP 400 mg every 4 weeks. Results. The ACR20/ACR50/ACR70 response rates of DB completers (n = 98) were 82.7{\%}/56.1{\%}/34.7{\%} at OLE entry, and 83.7{\%}/65.3{\%}/48.0{\%} at 52 weeks, respectively. Other clinical, functional, and radiographic outcomes were sustained during long-term administration of CZP, even without MTX. No new unexpected adverse events were observed during long-term CZP treatment. The efficacy and safety of CZP treatment were similar between the two dosing schedules. Conclusions. Long-term CZP administration is efficacious and safe for RA patients. No obvious differences in clinical efficacy and safety were observed between the two dosing schedules. The choice between two maintenace regimens adds flexibility in administration schedules for RA patients and physicians.",
keywords = "Certolizumab pegol, Monotherapy, Rheumatoid arthritis, TNF inhibitor, TNFα",
author = "Yoshiya Tanaka and Kazuhiko Yamamoto and Tsutomu Takeuchi and Hisashi Yamanaka and Naoki Ishiguro and Katsumi Eguchi and Akira Watanabe and Hideki Origasa and Toshiharu Shoji and Nobuyuki Miyasaka and Takao Koike",
year = "2014",
doi = "10.3109/14397595.2013.865822",
language = "English",
volume = "24",
pages = "725--733",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate

T2 - 52-week results from an open-label extension of the HIKARI study

AU - Tanaka, Yoshiya

AU - Yamamoto, Kazuhiko

AU - Takeuchi, Tsutomu

AU - Yamanaka, Hisashi

AU - Ishiguro, Naoki

AU - Eguchi, Katsumi

AU - Watanabe, Akira

AU - Origasa, Hideki

AU - Shoji, Toshiharu

AU - Miyasaka, Nobuyuki

AU - Koike, Takao

PY - 2014

Y1 - 2014

N2 - Objectives. To evaluate the long-term efficacy and safety of certolizumab pegol (CZP) treatment and to assess the efficacy of two CZP maintenance dosing schedules in Japanese rheumatoid arthritis (RA) patients who could not receive methotrexate (MTX). Methods. HIKARI double-blind (DB) patients were entered into an open-label extension (OLE) study. Patients withdrawn at 16 weeks due to lack of efficacy and DB completers without a 24-week American College of Rheumatology (ACR)20 response received CZP 200 mg every 2 weeks (Q2W). DB completers with 24-week ACR20 responses were randomized to CZP 200 mg Q2W or CZP 400 mg every 4 weeks. Results. The ACR20/ACR50/ACR70 response rates of DB completers (n = 98) were 82.7%/56.1%/34.7% at OLE entry, and 83.7%/65.3%/48.0% at 52 weeks, respectively. Other clinical, functional, and radiographic outcomes were sustained during long-term administration of CZP, even without MTX. No new unexpected adverse events were observed during long-term CZP treatment. The efficacy and safety of CZP treatment were similar between the two dosing schedules. Conclusions. Long-term CZP administration is efficacious and safe for RA patients. No obvious differences in clinical efficacy and safety were observed between the two dosing schedules. The choice between two maintenace regimens adds flexibility in administration schedules for RA patients and physicians.

AB - Objectives. To evaluate the long-term efficacy and safety of certolizumab pegol (CZP) treatment and to assess the efficacy of two CZP maintenance dosing schedules in Japanese rheumatoid arthritis (RA) patients who could not receive methotrexate (MTX). Methods. HIKARI double-blind (DB) patients were entered into an open-label extension (OLE) study. Patients withdrawn at 16 weeks due to lack of efficacy and DB completers without a 24-week American College of Rheumatology (ACR)20 response received CZP 200 mg every 2 weeks (Q2W). DB completers with 24-week ACR20 responses were randomized to CZP 200 mg Q2W or CZP 400 mg every 4 weeks. Results. The ACR20/ACR50/ACR70 response rates of DB completers (n = 98) were 82.7%/56.1%/34.7% at OLE entry, and 83.7%/65.3%/48.0% at 52 weeks, respectively. Other clinical, functional, and radiographic outcomes were sustained during long-term administration of CZP, even without MTX. No new unexpected adverse events were observed during long-term CZP treatment. The efficacy and safety of CZP treatment were similar between the two dosing schedules. Conclusions. Long-term CZP administration is efficacious and safe for RA patients. No obvious differences in clinical efficacy and safety were observed between the two dosing schedules. The choice between two maintenace regimens adds flexibility in administration schedules for RA patients and physicians.

KW - Certolizumab pegol

KW - Monotherapy

KW - Rheumatoid arthritis

KW - TNF inhibitor

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=84906303711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906303711&partnerID=8YFLogxK

U2 - 10.3109/14397595.2013.865822

DO - 10.3109/14397595.2013.865822

M3 - Article

C2 - 24372225

AN - SCOPUS:84906303711

VL - 24

SP - 725

EP - 733

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 5

ER -